Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04193735
Other study ID # 19069
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 17, 2020
Est. completion date December 30, 2024

Study information

Verified date February 2024
Source University of Nottingham
Contact Giles Major, PhD
Phone +44 115 8231035
Email giles.major@nottingham.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will explore the potential for a standardized MRI scan after a liquid meal to be used in diagnosis of the rare but debilitating chronic intestinal pseudo-obstruction (CIPO).


Description:

People with chronic intestinal pseudo-obstruction (CIPO) have problems digesting their food properly, due to a problem in their gut nerves or muscle. There are not many good tests to assess how a patient's stomach and bowels are working. Finding out more is the first step in developing a standardized clinical test using MRI to provide a faster diagnosis than is currently possible. Magnetic resonance imaging (MRI) scans allow the investigators to see inside the abdomen. Scans are not painful or harmful and are therefore ideal for repeated measurements. By scanning participants both before and after a test drink the investigators can see exactly how their digestion is working. The investigators are inviting 16 people who are at least 16 years old, 8 who have CIPO and 8 with chronic constipation, so the investigators can compare the images. Participants will come in for one half day of scanning. The investigators will take a total of 8 scans of their abdomens, every half hour. Participants will also fill in symptom questionnaires at every scan, for example if they feel bloated or have any abdominal pain. Each scan will take about 15 minutes and will require short breath holds. Participants will be able to get out of the scanner at any time point if they feel the need to. Participants will arrive fasted in the morning and will receive a test drink (a milk-based drink used as an oral nutritional supplement) right after the first scan. All participants will be asked to pause some of their usual medication that has a direct influence on digestion for 24h before the scan day and during the ~4h of the study. The primary outcome is peak small bowel motility, which the investigators hypothesize to be less active in people with CIPO. Other outcomes include gastric volume, small bowel water content and distribution, peak gastric motility, and gastrointestinal symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Ability to give informed consent - Sufficient level of English language to understand study information and respond to symptom questionnaires - CASES: a clinical diagnosis of primary or secondary Chronic Intestinal Pseudo-Obstruction, excluding adhesional obstruction. PICs will be asked to send clinical documentation that the diagnosis has been confirmed on crosssectional imaging. - CONTROLS: a Chronic constipation disorder diagnosed according to Rome IV criteria for functional constipation, constipation-predominant irritable bowel syndrome or opioid-induced constipation (diagnostic criteria as listed in Lacy et al 2016) Exclusion Criteria: - Inability to tolerate 400 ml liquid challenge meal (oral or through established gastrostomy; according to self-assessment) - Contra-indication to MRI scanning, such as metal implants, pacemaker etc - Pregnancy declared by candidate (no formal testing) - Inability to stop short-acting medications likely to alter small bowel motility, such as antiemetics, fast release opioids, laxatives, and anti-diarrhoeals, on the day before the study (24h before baseline scan; i.e. a total of circa 30h) as well as antibiotics for three days before the study. This only applies to long-term antibiotics commonly given for dysbiosis (small intestinal bacterial overgrowth). A short course of antibiotics given for acute infections will not be interrupted but the study day will be delayed until the course is finished. Patches, long acting formulations such as slow release medication or depot injection medication will be allowed to continue - Inability to omit parenteral nutrition for 12 hours before the fasting MRI scan (~16h total) - Medical comorbidity that means subject will not be able to undergo multiple scans e.g. severe respiratory disorder limiting time lying flat; severe musculoskeletal disorder limiting mobility - Previous small bowel resection (excluding ileostomy, insertion of venting tube or percutaneous endoscopic gastrostomy, appendectomy or cholecystectomy). Patients who have had a colectomy for their CIPO will be eligible. - Other gastrointestinal disorder likely to alter small bowel function e.g. uncontrolled coeliac disease, Crohn's disease. A diagnosis of small intestinal bacterial overgrowth will not be a reason for exclusion. PICs will be asked to supply information on resections and comorbidities for CIPO participants.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MRI scans after a liquid meal
Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times

Locations

Country Name City State
United Kingdom University of Nottingham Nottingham Nottinghamshire

Sponsors (8)

Lead Sponsor Collaborator
University of Nottingham Barts & The London NHS Trust, Cambridge University Hospitals NHS Foundation Trust, London North West Healthcare NHS Trust, Manchester University NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, Oxford University Hospitals NHS Trust, Pseudo-Obstruction Research Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak small gut motility after a test liquid meal Investigating whether people with CIPO have a lower peak small gut motility after a test drink than people who do not have CIPO. Small gut motility will be assessed with a standardised method on CineMRI, based on power spectrum analysis of voxel-signal changes with time (the outcome will be reported in arbitrary units). The primary outcome is peak small gut motility since a delay in motility (linked to one specific time point) would not be sufficient to explain the difference between CIPO and controls. up to 3.5 hours after meal, measured every half hour
Secondary Gastric emptying rate (ml/min) after a test liquid meal Investigating whether people with CIPO have slower gastric emptying after a test drink than people who do not have CIPO. The gastric emptying rate is determined by measuring the gastric volume every half hour after the standardised meal. up to 3.5 hours after meal, measured every half hour
Secondary Small bowel water volume (ml) after a test liquid meal Investigating whether people with CIPO have a greater volume of small bowel water after a test drink than people who do not have CIPO. Small bowel water content is determined from a heavily T2-weighted scan. The intensity threshold for free water will be set using each participant's spinal fluid, and only small bowel contents having an intensity equal to or greater than this value will be measured as small bowel free water volume. up to 3.5 hours after meal, measured every half hour
Secondary Gastric motility after a test liquid meal Investigating whether people with CIPO have a reduced gastric motility after a test drink than people who do not have CIPO. Gastric motility will be assessed with a standardised method on CineMRI, based on power spectrum analysis of voxel-signal changes with time (the outcome will be reported in arbitrary units). up to 3.5 hours after meal, measured every half hour
See also
  Status Clinical Trial Phase
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Active, not recruiting NCT04118699 - Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial Phase 2
Active, not recruiting NCT05724069 - Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). Phase 2
Completed NCT00793247 - Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP) Phase 2